Abstract 5201: Tuning gated CAR-T cells for enhanced activity against acute myeloid leukemia
Abstract Background: Conventional Chimeric Antigen Receptor (CAR) T-cell therapies for Acute Myeloid Leukemia (AML) face persistent challenges, including limited T-cell fitness, resistance emergence, and on-target, off-tumor toxicity. To overcome these limitations, we previously developed logically gated CAR-T cells using Synthetic Notch (SynNotch) circuits targeting two AML antigens, CD33 and CD123. In this system, CD33 engagement triggers expression of a gated CD123 CAR, leading to greater precision, improved metabolic fitness, reduced exhaustion, and longer in vivo persistence. Despite these benefits, gated CAR-T cells exhibit modestly reduced potency compared with conventional CAR-T cells. We hypothesize that incorporating modified intensity signaling elements into the gated architecture will enhance cytotoxicity while preserving the favorable metabolic and immunological profiles of gated CAR-T cells. Methods: To enhance downstream activation, we engineered a panel of CAR signaling constructs, including CD3ζ ITAM-modified and ZAP70-based signaling modules. These designs were assessed using an NFAT reporter assay, allowing quantification of inducible signaling strength across constructs. Results: Gated CAR-T cells expressing these enhanced signaling modules demonstrated accelerated and more robust activation, with a clear dose-dependent increase in NFAT reporter activity. Furthermore, we successfully incorporated the optimized signaling elements into a single open-reading-frame CAR design, enabling efficient expression and positioning these constructs for forthcoming translational testing. Conclusion: Augmenting T-cell receptor-proximal signaling within the gated CAR framework increases activation and improves functional potency. We anticipate that these high-intensity gated CAR-T cells will maintain the metabolic advantages characteristic of SynNotch-gated systems. Ongoing studies are evaluating their efficacy, fitness, and safety in relevant AML models. Citation Format: Shawn Barman, Molly Shields, Tatiana Fourfouris, Ki Jun Lee, Naiomi Desai, Devon Bell, Ethan BenDavid, Justin Pfahler, Ayesha Khan, Sanjana Tottempudi, Armita Shadfar, Yong-Mi Kim, BABAK MOGHIMI. Tuning gated CAR-T cells for enhanced activity against acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5201.
Authors
- Ethan BenDavid
- Molly C. Shields
- Shawn Barman (ORCID: https://orcid.org/0000-0003-0008-2811)
- Naiomi Desai
- Tatiana Fourfouris
- Babak Moghimi (ORCID: https://orcid.org/0000-0002-5154-832X)
- Yongmi Kim
- Armita Shadfar
- Ayesha Khan
- Devon Bell
- Justin Pfahler
- Sanjana Tottempudi
- Ki Jun Lee
Institutions
- APLA Health (US)
- Children's Hospital of Los Angeles (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2026-04-03
- DOI
- https://doi.org/10.1158/1538-7445.am2026-5201
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00